**Background of PLAU Antibody**
The PLAU gene encodes urokinase-type plasminogen activator (uPA), a serine protease critical for extracellular matrix degradation and cell migration by activating plasminogen to plasmin. uPA interacts with its receptor (uPAR) and inhibitors (PAI-1/2), forming a system implicated in tissue remodeling, wound healing, and pathological processes like cancer metastasis. Elevated uPA expression correlates with tumor invasiveness, poor prognosis, and therapeutic resistance, making it a biomarker and therapeutic target in oncology.
PLAU antibodies are immunological tools designed to detect and quantify uPA in research and diagnostics. They enable studies of uPA’s role in cancer progression, angiogenesis, and inflammation via techniques like immunohistochemistry, ELISA, and Western blot. These antibodies also aid in developing targeted therapies, such as uPA inhibitors or antibody-drug conjugates. Their specificity for different uPA forms (pro-enzyme, active, or complexes with inhibitors) enhances mechanistic insights into proteolytic cascades. As uPA’s dysregulation spans cancers, fibrosis, and cardiovascular diseases, PLAU antibodies remain vital for exploring its dual roles in physiology and disease, bridging translational research and clinical applications.